Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma

Authors

• Tariq Arshad, Bexion Pharmaceuticals
• Michael Gazda, Bexion Pharmaceuticals
• Gilles Tapolsky, Bexion Pharmaceuticals
• Jim Beach, Bexion Pharmaceuticals
• Daniel Blake Flora, St. Elizabeth Medical Center
• Reema Anil Patel, University of Kentucky
• Fa-Chyi Lee, University of California, Irvine
• Douglas B. Flora, Oncology Hematology Care, Edgewood, KY
• Davendra Sohal, University of Cincinnati Cancer Center
• Saima Sharif, University of Iowa
• Ki Young Chung, PRISMA Health Cancer Institute
• John L. Villano, University of Kentucky
• Vivek Sharma, James Graham Brown Cancer Center
• Julie Anne L. Gemmill, Stony Brook University Hospital
• Agustin Pimentel, University of Miami
• Nashat Y. Gabrail, Gabrail Cancer and Research Center
• Darryl Alan Outlaw, University of Alabama, Birmingham
• Ari David Baron, Pacific Hematology Oncology Associates
• Brian C. Boulmay, LSU Health Sciences Center – New OrleansFollow

Document Type

Conference Proceeding

Publication Date

1-11-2026

Publication Title

Journal of Clinical Oncology

Abstract

2026 ASCO Gastrointestinal Cancers Symposium

First Page

105

Last Page

105

Volume

44

Publisher

American Society of Clinical Oncology

Rights

Copyright © 2026 by the American Society of Clinical Oncology

Recommended Citation

Arshad, Tariq; Gazda, Michael; Tapolsky, Gilles; Beach, Jim; Flora, Daniel Blake; Patel, Reema Anil; Lee, Fa-Chyi; Flora, Douglas B.; Sohal, Davendra; Sharif, Saima; Chung, Ki Young; Villano, John L.; Sharma, Vivek; Gemmill, Julie Anne L.; Pimentel, Agustin; Gabrail, Nashat Y.; Outlaw, Darryl Alan; Baron, Ari David; and Boulmay, Brian C., "Bxq-350 in combination with FOLFOX7 and bevacizumab: Evaluation of effect on oxaliplatin-induced CIPN—A phase 1b/2 trial to assess the efficacy and safety of BXQ-350, a first-in-class sphingolipid metabolism modulator, in newly diagnosed metastatic colorectal carcinoma" (2026). School of Medicine Faculty Publications. 4823.
https://digitalscholar.lsuhsc.edu/som_facpubs/4823
10.1200/JCO.2026.44.2_suppl.105